An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer

Author： Vaishampayan U.   Fontana J.   Du W.   Hussain M.  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.60, Iss.6, 2002-12, pp. : 1050-1054

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer

By Guimaraes T.   Bento M.J.   Pinho T.   Guedes d.C.R.   Pinto F.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 159-159

Elsevier

Access to resources Recommend Favorite

The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

By Paule Bernard  

World Journal of Urology, Vol. 25, Iss. 5, 2007-10 ,pp. : 477-489

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

By Haas N.   Roth B.   Garay C.   Yeslow G.   Entmacher M.   Weinstein A.   Rogatko A.   Babb J.   Minnitti C.   Flinker D.   Gillon T.   Hudes G.  

Urology, Vol. 58, Iss. 1, 2001-07 ,pp. : 59-64

Elsevier

Access to resources Recommend Favorite

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

By Benaim E.A.   Pace C.M.   Lam P.M.   Roehrborn C.G.  

Urology, Vol. 59, Iss. 1, 2002-01 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite

Acid phosphatase: defining a role in androgen-independent prostate cancer

By Steineck G.   Kelly W.K.   Mazumdar M.   Vlamis V.   Schwartz M.   Scher H.I.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 719-726

Elsevier

Access to resources Recommend Favorite